Compounds > 1,23,25-trihydroxyvitamin d3
Page last updated: 2024-12-11

1,23,25-trihydroxyvitamin d3

Description

1,23,25-trihydroxyvitamin D3, also known as **calcitriol**, is the active form of vitamin D. It's a potent steroid hormone produced in the body through a series of steps starting with the conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin upon exposure to sunlight.

Here's why it's important for research:

**1. Role in Calcium Homeostasis and Bone Health:**
- Calcitriol is crucial for regulating calcium and phosphorus levels in the blood. It promotes calcium absorption from the intestines, bone resorption, and renal calcium reabsorption.
- Its deficiency can lead to rickets (in children) and osteomalacia (in adults), characterized by bone weakness and fractures.

**2. Beyond Bone Health: Diverse Biological Roles:**
- Research is revealing a wide range of functions for calcitriol beyond bone health:
- **Immune system:** Modulates immune responses, influencing autoimmune diseases and infectious diseases.
- **Cardiovascular health:** May play a role in blood pressure regulation and cardiovascular disease risk.
- **Cancer:** Studies suggest potential involvement in cancer prevention and treatment.
- **Metabolic health:** Impacts insulin sensitivity and glucose metabolism.
- **Neurological function:** Involved in brain development and function.

**3. Research Focus:**
- Understanding the mechanisms of action of calcitriol in different tissues and diseases.
- Developing new therapies based on calcitriol or its analogs for various conditions, including osteoporosis, autoimmune diseases, cardiovascular disease, and cancer.
- Exploring the potential of vitamin D supplementation in preventing and treating chronic diseases.

**4. Current Research:**
- Investigations are underway to explore calcitriol's potential benefits in:
- **COVID-19:** Studies suggest that adequate vitamin D levels may be associated with better outcomes.
- **Autoimmune diseases:** Calcitriol analogs are being explored as potential therapies for autoimmune disorders like multiple sclerosis.
- **Neurological disorders:** Research is examining the role of vitamin D in Alzheimer's disease and Parkinson's disease.

**5. Importance for Personalized Medicine:**
- Research into calcitriol's individual effects on various people is crucial for developing personalized therapies based on genetic predispositions and specific health conditions.

In conclusion, 1,23,25-trihydroxyvitamin D3 (calcitriol) is a vital hormone with diverse biological roles beyond its well-known effects on bone health. Research is uncovering its potential in various fields, including immunity, cardiovascular health, cancer, and metabolic disorders, making it a key target for drug development and personalized medicine approaches.

1,23,25-trihydroxyvitamin D3: intestinal metabolite of calcitriol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1alpha,23(S),25-trihydroxyvitamin D3 : A hydroxycalciol that consists of vitamin D3 (calciol) bearing additional hydroxy substituents at positions 1, 23 and 25 (with 1alpha,23S-configuration). An intermediate in the degradation pathway of 1alpha,25-(OH)2D3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9547450
CHEMBL ID3542380
CHEBI ID90970
MeSH IDM0116560

Synonyms (19)

Synonym
(23s)-1alpha,23,25-trihydroxyvitamin d3 / (23s)-1alpha,23,25-trihydroxycholecalciferol
(5z,7e)-(1s,3r,23s)-9,10-seco-5,7,10( 19)-cholestatriene-1,3,23,25-tetrol
LMST03020292
1,23,25-trihydroxyvitamin d3
1,23,25-trihydroxycholecalciferol
1alpha,23s,25-trihydroxycholecalciferol
(1s,3r,5z,7e,23s)-9,10-secocholesta-5,7,10-triene-1,3,23,25-tetrol
1alpha,23s,25-trihydroxy vitamin d3
CHEBI:90970
1alpha,23(s),25-trihydroxyvitamin d3
1alpha,23s,25-(oh)3d3
CHEMBL3542380
1a,23s,25-(oh)3d3
1a,23(s),25-trihydroxyvitamin d3
1a,23s,25-trihydroxy vitamin d3
1a,23s,25-trihydroxycholecalciferol
Q27162960
DTXSID201099678
(1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(1r,3s)-3,5-dihydroxy-1,5-dimethylhexyl]octahydro-7a-methyl-4h-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Hepatic biotransformation of 1α,25(OH)(2)D(3) by cytochrome P450 (P450) enzymes could be an important determinant of bioavailability in serum and tissues."( Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
Adomat, H; Deb, S; Guns, ES; Pandey, M, 2012)		0.38

Dosage Studied

ExcerptRelevanceReference
" A similar profile of metabolites was observed on high-pressure-liquid-chromatographic analysis of an extract from the kidneys of rats dosed intravenously with 1,25-dihydroxy[3H]cholecalciferol."( Production of C-24- and C-23-oxidized metabolites of 1,25-dihydroxycholecalciferol by cultured kidney cells (LLC PK1) and their presence in kidney in vivo.
Martin, CA; Napoli, JL, 1984)		0.27
" (23S)-1,23,25-Trihydroxyvitamin D3 had no intestinal calcium absorptive or bone calcium resorptive activity when dosed to vitamin D deficient rats at levels up to 500 ng."( (23S)-1,23,25-Trihydroxyvitamin D3: its biologic activity and role in 1 alpha,25-dihydroxyvitamin D3 26,23-lactone biosynthesis.
Baggiolini, EG; Engstrom, GW; Horst, RL; Napoli, JL; Uskoković, MR; Wovkulich, PM, 1984)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
hydroxycalciol
tetrolA polyol that contains 4 hydroxy groups.
D3 vitaminsA vitamin D that is calciol or its hydroxylated metabolites calcidiol and calcitriol. Calciol (also known as vitamin D3) acts as a hormone precursor, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.
hydroxy seco-steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Km7.10001.93005.90608.7000AID1218508
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID1218469Drug metabolism in human liver microsomes assessed as IC50 for ritonavir-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218461Drug metabolism in dexamethasone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2A inhibitor 8-methoxypsoralen2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218521Drug metabolism in prednisone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP1A1 inhibitor alpha-naphthoflavone2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218462Drug metabolism in CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2A inhibitor 8-methoxypsoralen2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218505Drug metabolism in dexamethasone treated CD1 mouse liver microsomes treated with 2 to 40 uM of 1alpha,25(OH)2D3 by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218492Drug metabolism in prednisone treated CD1 mouse liver microsomes treated with 20 uM of 1alpha,25(OH)2D3 assessed as metabolite formation after 30 mins by LC/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218518Drug metabolism in prednisone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP1A2 inhibitor furafyline2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218470Drug metabolism in human liver microsomes assessed as IC50 for ketoconazole-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218466Drug metabolism in prednisone treated CD1 mouse liver microsomes assessed as 1 uM CYP3A inhibitor-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218475Drug metabolism in human liver microsomes assessed as 1.24 uM docetaxel-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218472Drug metabolism in human liver microsomes assessed as IC50 for tamoxifen-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218478Drug metabolism in human liver microsomes assessed as 10 uM paclitaxel-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218526Drug metabolism in CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2C inhibitor sulfaphenazole2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218508Activity at human recombinant CYP3A4 treated with 2 to 40 uM of 1alpha,25(OH)2D3 by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218507Drug metabolism in human liver microsomes treated with 2 to 40 uM of 1alpha,25(OH)2D3 by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218463Drug metabolism in prednisone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2B inhibitor orphenadrine2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218468Drug metabolism in CD1 mouse liver microsomes assessed as 1 uM CYP3A inhibitor-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218460Drug metabolism in prednisone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2A inhibitor 8-methoxypsoralen2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218519Drug metabolism in dexamethasone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP1A2 inhibitor furafyline2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218520Drug metabolism in CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP1A2 inhibitor furafyline2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218477Drug metabolism in human liver microsomes assessed as 100 uM tamoxifen-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218528Drug metabolism in dexamethasone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2D inhibitor quinine2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218465Drug metabolism in CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2B inhibitor orphenadrine2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218467Drug metabolism in dexamethasone treated CD1 mouse liver microsomes assessed as 1 uM CYP3A inhibitor-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218457Drug metabolism in prednisone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2E inhibitor di-ethyldithiocarbamate2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218481Drug metabolism in human liver microsomes assessed as 100 uM chloramphenicol-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218522Drug metabolism in dexamethasone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP1A1 inhibitor alpha-naphthoflavone2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218476Drug metabolism in human liver microsomes assessed as 10 uM ritonavir-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218527Drug metabolism in prednisone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2D inhibitor quinine2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218471Drug metabolism in human liver microsomes assessed as IC50 for clarithromycin-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218499Drug level in dexamethasone treated CD1 mouse liver microsomes treated with 20 uM of 1alpha,25(OH)2D3 after 30 mins by LC/MS analysis in presence of NADPH relative to vehicle treated mouse2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218523Drug metabolism in CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP1A1 inhibitor alpha-naphthoflavone2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218458Drug metabolism in dexamethasone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2E inhibitor di-ethyldithiocarbamate2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218493Drug level in human liver microsomes assessed as retention time treated with 20 uM of 1alpha,25(OH)2D3 after 30 mins by LC/MS analysis in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218525Drug metabolism in dexamethasone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2C inhibitor sulfaphenazole2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218464Drug metabolism in dexamethasone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2B inhibitor orphenadrine2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218473Drug metabolism in human liver microsomes assessed as IC50 for docetaxel-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218474Drug metabolism in human liver microsomes assessed as 1 uM ketoconazole-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218506Drug metabolism in prednisone treated CD1 mouse liver microsomes treated with 2 to 40 uM of 1alpha,25(OH)2D3 by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218524Drug metabolism in prednisone treated CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2C inhibitor sulfaphenazole2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218479Drug metabolism in human liver microsomes assessed as 100 uM clarithromycin-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218480Drug metabolism in human liver microsomes assessed as 100 uM troleandromycin-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218459Drug metabolism in CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2E inhibitor di-ethyldithiocarbamate2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218529Drug metabolism in CD1 mouse liver microsomes assessed as metabolite formation at 20 uM after 30 mins by LC/MS analysis in presence of NADPH and CYP2D inhibitor quinine2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (71.43)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
triazolam
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.		2.0710triazolobenzodiazepinesedative
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		3.0610diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		4.4670D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
24,25-dihydroxyvitamin d 3
24,25-Dihydroxyvitamin D 3: A physiologically active metabolite of VITAMIN D. The compound is involved in the regulation of calcium metabolism, alkaline phosphatase activity, and enhancing the calcemic effect of CALCITRIOL.		1.9610
1,25-dihydroxyvitamin d3-26,23-lactone
[no description available]		2.3720vitamin D
1,24,25-trihydroxyvitamin d3
1,24,25-trihydroxyvitamin D3: RN given refers to (3beta,5Z,7E)-isomer		3.7730
ConditionIndicatedRelationship StrengthStudiesTrials
Deficiency, Vitamin D
[description not available]		01.9610
Vitamin D Deficiency
A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)		01.9610
chemdatabank.com